What is the strategic partnership between Eris Lifesciences and Natco Pharma?

Eris Lifesciences and Natco Pharma have partnered for the commercialization of semaglutide in India, with a planned launch in March 2026.

What is semaglutide used for?

Semaglutide is used for the management of Type 2 diabetes and chronic weight management.

Home / Business and Economy / Eris & Natco Forge Semaglutide Deal

Eris & Natco Forge Semaglutide Deal

Q: Has Natco Pharma received approval for semaglutide?

Yes, Natco Pharma recently received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture semaglutide for the Indian market.

24 Feb

•

Summary

Eris Lifesciences partners with Natco Pharma for semaglutide commercialisation.
Natco Pharma recently received approval to manufacture semaglutide.
Semaglutide targets Type 2 diabetes and chronic weight management.

Eris Lifesciences has announced a strategic collaboration with Natco Pharma for the commercialization of semaglutide within India. This partnership was established shortly after Natco Pharma secured approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture semaglutide for the Indian market.

The approval signifies a planned launch for March 2026. Semaglutide is poised to address the growing needs in India's metabolic care sector, particularly for Type 2 diabetes management. This move comes as several Indian pharmaceutical companies prepare for the upcoming patent expiry of Semaglutide in the country next month.